BPGbio Updates Phase 2 Glioblastoma Data at ESMO 2026

BPGbio ESMO 2026 GBM Phase 2 Trial Data Update

BPGbio Presents Phase 2 Glioblastoma Data Update at ESMO Congress 2026, Highlighting Median Overall Survival of 19.9 Months in MGMT-Unmethylated Patients

Format

PNG

Source

BPGbio

Downloads